1. Report Introduction 2. Methicillin-resistant Staphylococcus aureus (MRSA) Market Overview at a Glance 2.1. Market Share Distribution of Methicillin-resistant Staphylococcus aureus (MRSA) in 2016 2.2. Market Share Distribution of Methicillin-resistant Staphylococcus aureus (MRSA) in 2028 3. Disease Background and Overview: Methicillin-resistant Staphylococcus aureus (MRSA) 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM 4.3. Total Prevalent Patient Population of Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM – By Countries 5. Epidemiology of Methicillin-resistant Staphylococcus aureus (MRSA) by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.1.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) * 5.1.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) * 5.1.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.1.6. Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.4.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) * 5.4.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) * 5.4.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.4.6. Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.5.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) * 5.5.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) * 5.5.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.5.6. Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.6.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) * 5.6.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) * 5.6.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.6.6. Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.7.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) * 5.7.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) * 5.7.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.7.6. Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.8.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) * 5.8.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) * 5.8.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.8.6. Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.9.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) * 5.9.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) * 5.9.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 5.9.6. Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Methicillin-resistant Staphylococcus aureus (MRSA) 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Methicillin-resistant Staphylococcus aureus (MRSA) 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Methicillin-resistant Staphylococcus aureus (MRSA) : 7MM Market Analysis 12.1. 7MM Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) 12.2. 7MM Percentage Share of drugs marketed for Methicillin-resistant Staphylococcus aureus (MRSA) 12.3. 7MM Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Products 13. Methicillin-resistant Staphylococcus aureus (MRSA) : Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in United States 13.1.2. Percentage Share of drugs marketed for Methicillin-resistant Staphylococcus aureus (MRSA) in United States 13.1.3. Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in Germany 13.2.1.2. Percentage Share of drugs marketed for Methicillin-resistant Staphylococcus aureus (MRSA) in Germany 13.2.1.3. Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in France 13.2.2.2. Percentage Share of drugs marketed for Methicillin-resistant Staphylococcus aureus (MRSA) in France 13.2.2.3. Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in Italy 13.2.3.2. Percentage Share of drugs marketed for Methicillin-resistant Staphylococcus aureus (MRSA) in Italy 13.2.3.3. Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in Spain 13.2.4.2. Percentage Share of drugs marketed for Methicillin-resistant Staphylococcus aureus (MRSA) in Spain 13.2.4.3. Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Methicillin-resistant Staphylococcus aureus (MRSA) in United Kingdom 13.2.5.3. Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in Japan 13.3.2. Percentage Share of drugs marketed for Methicillin-resistant Staphylococcus aureus (MRSA) in Japan 13.3.3. Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight *Indication Specific

Table 1: Total Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM Table 2: Total Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM by Countries Table 3: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028) Table 4: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028) Table 5: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028) Table 6: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028) Table 7: Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028) Table 8: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) Table 9: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) Table 10: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) Table 11: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) Table 12: Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) Table 13: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) Table 14: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) Table 15: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) Table 16: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) Table 17: Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) Table 18: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) Table 19: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) Table 20: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) Table 21: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) Table 22: Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) Table 23: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) Table 24: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) Table 25: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) Table 26: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) Table 27: Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) Table 28: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) Table 29: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) Table 30: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) Table 31: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) Table 32: Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) Table 33: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) Table 34: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) Table 35: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) Table 36: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) Table 37: Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in USD MM (2016-2028) Table 42:7MM- Market Share Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Table 43:7MM- Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Table 44: United States-Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in USD MM (2016-2028) Table 45: United States-Market Share Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Table 46: United States-Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Table 47: Germany-Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in USD MM (2016-2028) Table 48: Germany-Market Share Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Table 49: Germany-Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Table 50: France-Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in USD MM (2016-2028) Table 51: France-Market Share Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Table 52: France-Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Table 53: Italy-Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in USD MM (2016-2028) Table 54: Italy-Market Share Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Table 55: Italy-Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Table 56: Spain-Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in USD MM (2016-2028) Table 57: Spain-Market Share Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Table 58: Spain-Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Table 59:UK-Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in USD MM (2016-2028) Table 60:UK-Market Share Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Table 61:UK-Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Table 62: Japan-Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in USD MM (2016-2028) Table 63: Japan-Market Share Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Table 64: Japan-Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Figure 1: Total Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM Figure 2: Total Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028) Figure 4: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028) Figure 5: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028) Figure 6: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028) Figure 7: Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028) Figure 8: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) Figure 9: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) Figure 10: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) Figure 11: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) Figure 12: Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) Figure 13: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) Figure 14: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) Figure 15: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) Figure 16: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) Figure 17: Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) Figure 18: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) Figure 19: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) Figure 20: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) Figure 21: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) Figure 22: Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) Figure 23: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) Figure 24: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) Figure 25: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) Figure 26: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) Figure 27: Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) Figure 28: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) Figure 29: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) Figure 30: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) Figure 31: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) Figure 32: Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) Figure 33: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) Figure 34: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) Figure 35: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) Figure 36: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) Figure 37: Treatable Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in USD MM (2016-2028) Figure 42:7MM- Market Share Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Figure 43:7MM- Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Figure 44: United States-Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in USD MM (2016-2028) Figure 45: United States-Market Share Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Figure 46: United States-Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Figure 47: Germany-Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in USD MM (2016-2028) Figure 48: Germany-Market Share Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Figure 49: Germany-Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Figure 50: France-Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in USD MM (2016-2028) Figure 51: France-Market Share Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Figure 52: France-Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Figure 53: Italy-Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in USD MM (2016-2028) Figure 54: Italy-Market Share Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Figure 55: Italy-Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Figure 56: Spain-Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in USD MM (2016-2028) Figure 57: Spain-Market Share Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Figure 58: Spain-Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Figure 59:UK-Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in USD MM (2016-2028) Figure 60:UK-Market Share Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Figure 61:UK-Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Figure 62: Japan-Market Size of Methicillin-resistant Staphylococcus aureus (MRSA) in USD MM (2016-2028) Figure 63: Japan-Market Share Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028) Figure 64: Japan-Market Sales of Methicillin-resistant Staphylococcus aureus (MRSA) by Therapies in USD MM (2016-2028)